| ￥3500 | |
| Z06380-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Mouse RANKL, His Tag at 0.5μg/ml (100μl/well) on the plate can bind TNFRSF11A/Rank hFc Chimera, Mouse. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 47.0 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 57-67 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | TNFRSF11A, also known as receptor activator of NF-κB (RANK), activates several signaling pathways, such as NF-κB, JNK, ERK, p38α, and Akt/PKB. RANK/TNFRSF11A is a novel and frequent target for de novo methylation in gliomas, which affects apoptotic activity and focus formation thereby contributing to the molecular pathogenesis of gliomas. |
| Synonyms | ODFR; Receptor activator of NF-KB; NF-KB; NFKB; CD265; TNFRSF11A; Rank; FEO; LOH18CR1; OPTB7; OSTS; PDB2; TRANCER; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
